Onco-hematologia
Estudo de coorte | Características e história natural da amiloidose cardíaca por transtirretina em estágio inicial.
30 Mai, 2022 | 13:07hEditorial: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities
Comentário no Twitter
The natural history of Transthyretin Amyloid Cardiomyopathy (ATTR-CM): disease course and clinical outcome among patients diagnosed with early-stage of disease!#amyloid #heart #failure #cardiac #amyloidosis@escardio @ESC_Journals
https://t.co/uvydC3gisD pic.twitter.com/ooKyjeGVNe
— EHJ Editor-in-Chief (@ehj_ed) May 25, 2022
Sob licença de https://creativecommons.org/licenses/by-nc/4.0/
Navegando pela toxicidade financeira em pacientes com câncer: uma abordagem de tratamento multidisciplinar.
27 Mai, 2022 | 13:37hConteúdos relacionados:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Segunda revisão do International Staging System (R2-ISS) para sobrevida geral no mieloma múltiplo.
27 Mai, 2022 | 13:23hEstudo de coorte | Risco de tromboembolismo venoso em homens com câncer de próstata em comparação com homens na população geral.
26 Mai, 2022 | 12:56hComunicado de imprensa: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Comentário no Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Sob licença de http://creativecommons.org/licenses/by-nc/4.0/
Identificação de mieloma múltiplo de alto risco com um perfil transcriptômico de célula plasmática leucemia-like.
24 Mai, 2022 | 11:21h
Comentário no Twitter
A transcriptomic primary plasma cell leukaemia classifier comprising 53 genes had a sensitivity of 93% in pts with newly-diagnosed MM. Multivariate analysis confirmed the prognostic performance of this classifier vs the International Staging System: https://t.co/bD45PQG9bl #MMSM
— NatureRevClinOncol (@NatRevClinOncol) April 7, 2022
Estudo randomizado | Adição de elotuzumabe à lenalidomida e à dexametasona para pacientes com mieloma múltiplo recém-diagnosticado e inelegível a transplante.
20 Mai, 2022 | 13:36hAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link para o resumo – $ para o texto completo)
Comentário: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser
Comentário no Twitter
NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN
— The Lancet Haematology (@TheLancetHaem) May 12, 2022
Série “Como Tratar” sobre discrasias de células plasmáticas.
19 Mai, 2022 | 12:39hEditorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood
How I treat relapsed multiple myeloma – Blood
How I treat frontline transplantation-eligible multiple myeloma – Blood
Estudo randomizado | Ibrutinibe-venetoclax com duração fixa em pacientes com leucemia linfocítica crônica e comorbidades.
17 Mai, 2022 | 11:48h
Comentário no Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022
Análise de dados individuais de 258 registros de câncer em 61 países | Tendências mundiais na sobrevida de base populacional para crianças, adolescentes e jovens adultos diagnosticados com leucemia, por subtipo, entre 2000-2014.
13 Mai, 2022 | 12:40h5 principais desafios da gestão de antibióticos em doenças infecciosas relacionadas a transplante e estratégias práticas para abordá-las.
2 Mai, 2022 | 13:55h
Comentário no Twitter
🆕💥Review Article @ASHE_Journal
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/ToPLQXtC4r pic.twitter.com/pZQWWb3ZSx— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) April 28, 2022
Sob licença de http://creativecommons.org/licenses/by/4.0/